Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with ...

Businessman and entrepreneur Mark Cuban recently discussed leadership with Leadership Lab columnist Michael Pietrack. The ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

In this deep dive BioSpace explores the opportunities and challenges presented by the FDA’s accelerated approval program.